Ann Arbor, MI, United States of America

Irfan A Asangani

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.2

ph-index = 3

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Irfan A. Asangani: Innovator in Cancer Therapeutics**

Introduction

Irfan A. Asangani is a notable inventor based in Ann Arbor, MI, recognized for his significant contributions to the field of therapeutic methods targeting BET bromodomains. With a robust portfolio of five patents, Asangani is at the forefront of innovations aimed at treating various cancers.

Latest Patents

Asangani’s latest patents include groundbreaking work on BET bromodomain inhibitors and therapeutic methods. These patents disclose compositions that not only inhibit BET bromodomains but also present methods for utilizing these inhibitors in the treatment of diseases where BET bromodomain inhibition is beneficial, especially various forms of cancer. His work on substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles further expands the toolkit available for treating conditions responsive to BET bromodomain inhibition. The compounds he has developed are particularly promising for cancer treatment, showcasing Asangani’s dedication to advancing cancer therapies.

Career Highlights

Irfan A. Asangani is associated with the University of Michigan, where he engages in cutting-edge research aimed at developing innovative cancer treatments. His expertise in pharmacological sciences and medicinal chemistry has been instrumental in driving forward new therapeutic options.

Collaborations

Throughout his career, Asangani has collaborated with respected peers such as Arul M. Chinnaiyan and Shaomeng Wang. These collaborations highlight the importance of teamwork in scientific research and innovation, contributing to the advancement of understanding in the field of cancer therapeutics.

Conclusion

Irfan A. Asangani stands out as an influential inventor in the domain of cancer research, with multiple patents under his name. His focus on BET bromodomain inhibitors positions him as a key contributor to the development of novel therapeutic approaches in oncology. With ongoing research and collaboration, Asangani continues to impact the landscape of cancer treatment positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…